GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Syros Pharmaceuticals SYRS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Syros Pharmaceuticals — daily SYRS Delayed
Market value
$10,732
Last close × shares
Volume
3.1k
Shares, 9 Nov 2026

About Syros Pharmaceuticals

Its shares trade under the ticker SYRS. It has been listed since 30 June 2016. In the fiscal year to 31 December 2023, it reported revenue of $9.9m and a net loss of $164.6m. At that date it held total assets of $168.2m and shareholders' equity of $16.7m.

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2016-06-30. The firm is focused on redefining the power of small molecules to control the expression of genes. The company is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.

Figures and description from our data supplier, not checked against the company's own report.

More about Syros Pharmaceuticals →

Latest on Syros Pharmaceuticals

Our reporting

We have not reported on Syros Pharmaceuticals yet.

Next results

31 Mar 2027

Due on 31 Mar 2027. Analysts expect earnings of -4.38 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Syros Pharmaceuticals's ticker?

Syros Pharmaceuticals trades as SYRS on its US listing, under ISIN US87184Q2066.

What was Syros Pharmaceuticals's last closing price?

0.00 on 9 Nov 2026. The figure is in USD and is never converted.

When does Syros Pharmaceuticals next report results?

Results are expected on 31 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.